{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:19:10Z","timestamp":1782461950232,"version":"3.54.5"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T00:00:00Z","timestamp":1533513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Castle Biosciences, Inc"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jaad.2018.07.028","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T22:53:05Z","timestamp":1533336785000},"page":"149-157.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria"],"prefix":"10.1016","volume":"80","author":[{"given":"Brian R.","family":"Gastman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedram","family":"Gerami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Kurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sancy","family":"Leachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Vetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2018.07.028_bib1","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"36","key":"10.1016\/j.jaad.2018.07.028_bib2","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.028_bib3","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.028_bib4","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jaad.2018.07.028_bib5","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973-2014), National Cancer Institute, DCCPS, Surveillance Research Program, released April 2017, based on the November 2016 submission."},{"issue":"2","key":"10.1016\/j.jaad.2018.07.028_bib6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2016.10.018","article-title":"Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992-2013","volume":"76","author":"Landow","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.07.028_bib7","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/jid.2014.452","article-title":"More people die from thin melanomas (\u2a7d1\u2009mm) than from thick melanomas (>4\u2009mm) in\u00a0Queensland, Australia","volume":"135","author":"Whiteman","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"5 Suppl 1","key":"10.1016\/j.jaad.2018.07.028_bib8","first-page":"S17","article-title":"Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006","volume":"65","author":"Jemal","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.028_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv294","article-title":"Melanoma thickness and survival trends in the United States, 1989\u20132009","volume":"108","author":"Shaikh","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaad.2018.07.028_bib10","unstructured":"Coit DG, Thompson J, Albertini MR. NCCN Clinical Practice Guidelines in Oncology. Melanoma. Version 3.2018. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/melanoma.pdf. Accessed July 12, 2018."},{"issue":"3","key":"10.1016\/j.jaad.2018.07.028_bib11","doi-asserted-by":"crossref","first-page":"366","DOI":"10.6004\/jnccn.2012.0036","article-title":"Melanoma","volume":"10","author":"Coit","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.jaad.2018.07.028_bib12","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jaad.2016.02.1229","article-title":"Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: a prospective cohort study","volume":"75","author":"Podlipnik","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.07.028_bib13","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1245\/s10434-017-5768-8","article-title":"Routine computer tomography imaging for the detection of recurrences in high-risk melanoma patients","volume":"24","author":"Park","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.028_bib14","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ejca.2015.01.007","article-title":"Prospective evaluation of follow-up in melanoma patients in Germany \u2013 results of a multicentre and longitudinal study","volume":"51","author":"Livingstone","year":"2015","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.jaad.2018.07.028_bib15","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1200\/JCO.2003.01.091","article-title":"Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy","volume":"21","author":"Garbe","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.07.028_bib16","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/CMR.0b013e32833716f9","article-title":"Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?","volume":"20","author":"Leiter","year":"2010","journal-title":"Melanoma Res"},{"issue":"4","key":"10.1016\/j.jaad.2018.07.028_bib17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/CMR.0000000000000344","article-title":"Association between the use of surveillance PET\/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma","volume":"27","author":"Leon-Ferre","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2018.07.028_bib18","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","article-title":"Long-term outcomes in patients with BRAFV600\u2013mutant metastatic melanoma who received dabrafenib combined with trametinib","volume":"36","author":"Long","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.028_bib19","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1186\/s40425-014-0040-2","article-title":"Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome","volume":"2","author":"Nishino","year":"2014","journal-title":"J Immunother Cancer"},{"issue":"15","key":"10.1016\/j.jaad.2018.07.028_bib20","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.jaad.2018.07.028_bib21","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.07.028_bib22","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2017.75.6270","article-title":"Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma","volume":"36","author":"Robert","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.028_bib23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/1078-0432.CCR-13-3316","article-title":"Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma","volume":"21","author":"Gerami","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.028_bib24","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jaad.2015.01.009","article-title":"Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy","volume":"72","author":"Gerami","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.028_bib25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12885-018-4016-3","article-title":"Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients","volume":"18","author":"Zager","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.028_bib26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13045-017-0520-1","article-title":"Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test","volume":"10","author":"Hsueh","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"16","key":"10.1016\/j.jaad.2018.07.028_bib27","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jaad.2018.07.028_bib28","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/cncr.23359","article-title":"Age and gender are significant independent predictors of survival in primary cutaneous melanoma","volume":"112","author":"Lasithiotakis","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.jaad.2018.07.028_bib29","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1245\/s10434-013-3100-9","article-title":"Age as a prognostic factor in patients with localized melanoma and\u00a0regional metastases","volume":"20","author":"Balch","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.jaad.2018.07.028_bib30","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2018.07.028_bib31","first-page":"196","article-title":"Impact of gene expression profiling on decision-making in clinically node negative melanoma patients after surgical staging","volume":"17","author":"Schuitevoerder","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.028_bib32","first-page":"544","article-title":"Factors affecting dermatologists' use of a 31-gene expression profiling test as an adjunct for predicting metastatic risk in cutaneous melanoma","volume":"17","author":"Svoboda","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2018.07.028_bib33","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1080\/03007995.2016.1192997","article-title":"Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients","volume":"32","author":"Berger","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaad.2018.07.028_bib34","doi-asserted-by":"crossref","unstructured":"Dillon LD, Gadzia JE, of RDSTJ, 2018. Prospective, multicenter clinical impact evaluation of a 31-gene expression profile test for management of melanoma patients. Skin J Cut Med. 2018;2(2).","DOI":"10.25251\/skin.2.2.3"},{"issue":"4","key":"10.1016\/j.jaad.2018.07.028_bib35","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.det.2017.06.017","article-title":"Assessing genetic expression profiles in melanoma prognosis","volume":"35","author":"Farberg","year":"2017","journal-title":"Dermatol Clin"},{"issue":"2","key":"10.1016\/j.jaad.2018.07.028_bib36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00432-012-1322-z","article-title":"A nine-gene signature predicting clinical outcome in cutaneous melanoma","volume":"139","author":"Brunner","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"10.1016\/j.jaad.2018.07.028_bib37","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/jid.2014.85","article-title":"Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease","volume":"134","author":"Sivendran","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"23","key":"10.1016\/j.jaad.2018.07.028_bib38","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2014.60.7002","article-title":"Tumor cell adhesion as a risk factor for sentinel lymph node metastasis in primary cutaneous melanoma","volume":"33","author":"Meves","year":"2015","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.jaad.2018.07.028_bib39","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1200\/JCO.2013.54.2340","article-title":"Prediction of survival in patients with thin melanoma: results from a multi-institution study","volume":"32","author":"Maurichi","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.028_bib40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jamcollsurg.2013.03.007","article-title":"Late recurrence in melanoma: clinical implications of lost dormancy","volume":"217","author":"Faries","year":"2013","journal-title":"J Am Coll Surg"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.028_bib41","first-page":"93","article-title":"Variations in supportive care needs of patients after diagnosis of localised cutaneous melanoma: a 2-year follow-up study","volume":"25","author":"Beesley","year":"2017","journal-title":"Support Care Cancer"},{"issue":"36","key":"10.1016\/j.jaad.2018.07.028_bib42","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1200\/JCO.2016.68.2278","article-title":"Psychoeducational intervention to reduce fear of cancer recurrence in people at high risk of developing another primary melanoma: results of a randomized controlled trial","volume":"34","author":"Dieng","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jaad.2018.07.028_bib43","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdu366","article-title":"Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma","volume":"25","author":"Molassiotis","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.028_bib44","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jaad.2015.09.008","article-title":"Discordance of histopathologic parameters in cutaneous melanoma: clinical implications","volume":"74","author":"Patrawala","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.07.028_bib45","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.2009.24.7734","article-title":"Pathology review of thin melanoma and melanoma in situ in a multidisciplinary melanoma clinic: impact on treatment decisions","volume":"28","author":"Santillan","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.07.028_bib46","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S1470-2045(18)30106-2","article-title":"Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"19","author":"Maio","year":"2018","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.jaad.2018.07.028_bib47","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jaad.2018.07.028_bib48","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218323284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218323284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:47:42Z","timestamp":1759272462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218323284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0190962218323284"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.07.028","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}